Lapse and Forfeit of Unlisted Conditional Performance Rights
12 April 2017 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read More
CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
12 April 2017 CLINUVEL today announced that it had reached agreement with...
Read More
Appendix 4D and Half Year Report
24 February 2017 Your Directors present their report on the Company and...
Read More
CLINUVEL Newsletter - February 2017
16 February 2017 I wish all stakeholders of the CLINUVEL Group a...
Read More
Appendix 4C - Quarterly report
31 January 2017 Enclosed is the quarterly report for the period ending...
Read More
CLINUVEL Newsletter - December 2016
20 December 2016 At the end of a calendar year we look...
Read More
Results of Meeting
28 November 2016 In accordance with Listing Rule 3.13.2 and section 251AA...
Read More
Chair's Address to the Annual General Meeting
27 November 2017 I would like to commence my address by saying...
Read More